Spots Global Cancer Trial Database for tumors
Every month we try and update this database with for tumors cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Trial of Two Schedules of Perifosine for Patients With Solid Tumors or Lymphomas | NCT00389077 | Tumors Lymphomas | Perifosine | 18 Years - | AEterna Zentaris | |
| This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas | NCT02171260 | Pediatrics Solid Tumors | Eribulin Mesyla... | 6 Months - 17 Years | Eisai Inc. | |
| Study Evaluating TTI-237 in Advanced Malignant Solid Tumors. | NCT00195325 | Tumors Neoplasms | TTI-237 | 18 Years - | Wyeth is now a wholly owned subsidiary of Pfizer | |
| An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors | NCT00514267 | Prostate Cancer Tumors | YM 155 Docetaxel Prednisone | 18 Years - | Astellas Pharma Inc | |
| One Time Injection of Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy | NCT00358397 | Tumors | Clostridium nov... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA | NCT01269853 | Glioblastoma Mu... Anaplastic Astr... | Bevacizumab Bevacizumab | 18 Years - | Northwell Health | |
| Safety and Efficacy of Cryoablation for Metastatic Lung Tumors | NCT01307501 | Metastatic Lung... | Cryoablation | 18 Years - | Boston Scientific Corporation | |
| NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS) | NCT00248404 | Tumors | NB1011 | 18 Years - | Kiadis Pharma | |
| Optimal Application Dose of Superficial Hyperthermia | NCT00766233 | Tumors | Hyperthermal tr... | 18 Years - | Universitätsmedizin Mannheim | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| A Study of ASP1951 in Subjects With Advanced Solid Tumors | NCT03799003 | Advanced Solid ... | ASP1951 pembrolizumab | 18 Years - | Astellas Pharma Inc | |
| A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors | NCT00495144 | Tumors Hypoxia | TH-302 | 18 Years - | Threshold Pharmaceuticals | |
| MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies | NCT01235897 | Advanced Solid ... Tumors Cancer | MK-2206 Paclitaxel Trastuzumab | 18 Years - | University of California, San Francisco | |
| A Study of 5 Fluorouracil and the Anti-Tumor Activity of ADH300004 and 5 Fluorouracil in Subjects With Incurable Solid Tumors | NCT00264472 | Neoplasms | ADH300004 | 18 Years - | Adherex Technologies, Inc. | |
| Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors | NCT00201812 | Tumors | Etanercept Docetaxel Dexamethasone | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors | NCT01031719 | H1N1 Influenza ... Invasive Solid ... | adjuvanted A(H1... non-adjuvanted ... non-adjuvanted ... | 2 Years - 70 Years | Chiltern Pesquisa Clinica Ltda | |
| Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization | NCT00434109 | Neuroendocrine ... Islet Cell Tumo... | Sunitinib malat... Hepatic Artery ... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours | NCT00264004 | Tumors | AZD2171 | 18 Years - | AstraZeneca | |
| A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors | NCT01664000 | Solid Tumors | thioureidobutyr... | 18 Years - | Cellceutix Corporation | |
| First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors | NCT01609556 | Tumors | Mirvetuximab so... | 18 Years - | ImmunoGen, Inc. | |
| Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors | NCT00345189 | Tumors Lymphoma | CNF2024 | 18 Years - | Biogen | |
| Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors | NCT05081180 | Central Nervous... | Avelumab Lenvatinib | 2 Years - 18 Years | EMD Serono | |
| A Study to Evaluate the Effect of Far Infrared Radiation for Cancer Treatment | NCT00574106 | Neoplasms | Far Infrared Ra... | - | GAAD Medical Research Institute Inc. | |
| Research on the Application and Mechanism of New Biological Probes in Biomedicine | NCT04977739 | Tumors Cardiovascular ... Respiratory Sys... Digestive Syste... Endocrine Syste... Metabolic Disea... Immune System D... Urinary System ... Nervous System ... Blood Diseases Infectious Dise... | No intervention | 18 Years - 70 Years | Nanfang Hospital, Southern Medical University | |
| A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors | NCT00728793 | Tumors | CUDC-101 | 18 Years - | Curis, Inc. | |
| Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma | NCT01091883 | Bone Cancer Bone Metastases Pain | Exablate treatm... Radiation | 18 Years - | InSightec | |
| Study Evaluating TTI-237 in Advanced Malignant Solid Tumors | NCT00195247 | Neoplasms | TTI-237 | 18 Years - | Wyeth is now a wholly owned subsidiary of Pfizer | |
| A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4 | NCT01409135 | Tumors Medical Oncolog... Neoplasms | AGS-22M6E ASG-22CE | 18 Years - | Astellas Pharma Inc | |
| Dose Escalation Study of SH U04722 in Solid Tumors | NCT00375453 | Tumors | SH U04722 | 20 Years - 74 Years | Bayer | |
| Assessment of Functional and Symptom Outcomes for Survivors of Paranasal Sinus, Nasopharyngeal and Skull Base Tumors | NCT05733091 | Tumors | Standard of Car... | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors | NCT01980667 | Advanced Solid ... | lurbinectedin (... Cisplatin | 18 Years - | PharmaMar | |
| CDK4/6 Tumor, Abemaciclib, Paclitaxel | NCT04594005 | Tumors | abemaciclib+pac... | 19 Years - | Yonsei University | |
| XACT ACE Observational Registry | NCT04950959 | Tumors | Hands-free, use... | 18 Years - | Xact Robotics Ltd. | |
| A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | NCT03260322 | Advanced Solid ... | ASP8374 Pembrolizumab | 18 Years - | Astellas Pharma Inc | |
| A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors | NCT06389526 | Advanced or Met... | CHS-1000 Toripalimab | 18 Years - | Coherus Biosciences, Inc. | |
| Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors | NCT00091806 | Tumors Oncology Solid Tumors | panitumumab (AB... Panitumumab | 18 Years - | Amgen | |
| Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone | NCT02532634 | Cancer Tumors | ramosetron, apr... palonosetron, a... | 19 Years - | Kangdong Sacred Heart Hospital | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients | NCT00613652 | Cancer Tumors Carcinoma | AZD4877 | 20 Years - 75 Years | AstraZeneca | |
| Assessment of Functional and Symptom Outcomes for Survivors of Paranasal Sinus, Nasopharyngeal and Skull Base Tumors | NCT05733091 | Tumors | Standard of Car... | 18 Years - | M.D. Anderson Cancer Center | |
| Ph Ib/BGJ398/Cervix and Other Solid Tumors | NCT02312804 | Cancer of Cervi... Tumors | BGJ398 Carboplatin Paclitaxel | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| A Phase I Study of G3139 Subcutaneous in Solid Tumors | NCT00543231 | Tumors | G3139, Oblimers... | 18 Years - | Genta Incorporated | |
| Study of BMS-663513 in Patients With Advanced Cancer | NCT00309023 | Tumors | BMS-663513 | 18 Years - | Bristol-Myers Squibb | |
| Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors | NCT00093873 | Tumors | Anti-angiogenes... AMG 706 | 18 Years - | Amgen | |
| Study Evaluating TTI-237 in Advanced Malignant Solid Tumors. | NCT00195325 | Tumors Neoplasms | TTI-237 | 18 Years - | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Safety Study of X-82 in Patients With Advanced Solid Tumors | NCT01296581 | Advanced Solid ... | X-82 | 18 Years - | Tyrogenex | |
| Study of Dasatinib in Patients With Advanced Solid Tumors | NCT00162214 | Tumors | Dasatinib + Ket... | 18 Years - | Bristol-Myers Squibb | |
| QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors | NCT00974896 | Advanced Malign... Advanced Solid ... Cancer Solid Tumors Tumors | AMG 479 | 18 Years - | NantCell, Inc. | |
| HP Pyruvate MRI in Cancers | NCT05697406 | Image Warburg Effect Tumors | Hyperpolarized ... | 18 Years - 88 Years | University of Maryland, Baltimore | |
| A Study Of PF-06664178 In Patients With Advanced Solid Tumors | NCT02122146 | Neoplasms | PF-06664178 PF-06664178 | 18 Years - | Pfizer | |
| Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy | NCT00222443 | Lymphomas Tumors | Irinotecan | 1 Year - 21 Years | University of Oklahoma | |
| A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer | NCT00653939 | Tumors | Fosbretabulin Carboplatin Paclitaxel Bevacizumab | 18 Years - | Mateon Therapeutics | |
| Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic | NCT00127829 | Tumors | Gefitinib | 18 Years - | AstraZeneca | |
| 18F-Fluorodeoxyglucose Positron Emission Tomography in Oncology and Neurology | NCT01180751 | Tumors | [18F]-Fluorodeo... | 18 Years - | University of Manitoba | |
| Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors | NCT01970540 | Endometrial Ade... Neuroendocrine ... Small-cell Lung... | lurbinectedin (... Doxorubicin | 18 Years - 75 Years | PharmaMar | |
| Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED) | NCT00060645 | Tumors Lymphoma Multiple Myelom... | ridaforolimus | 18 Years - | Merck Sharp & Dohme LLC | |
| ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain | NCT00981578 | Bone Metastases | ExAblate 2100 | 18 Years - | InSightec | |
| Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy Subjects | NCT00777530 | Breast Cancer Tumors Leukemia | Bosutinib (SKI-... | 18 Years - 50 Years | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy | NCT00230217 | Tumors Hyperuricemia Tumor Lysis Syn... | Rasburicase (SR... | - | Sanofi | |
| A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors | NCT02549937 | Tumors | surufatinib | 18 Years - | Hutchmed | |
| Assay Development for Cancer Biomarkers | NCT02874729 | Tumors | Venesection Urine collectio... Sputum collecti... Bronchoalveolar... | 18 Years - | King's College London | |
| Sodium Fluorescein-Guided Resection of Pediatric Neurosurgical Tumors | NCT03752203 | Pediatric Neuro... | Sodium Fluoresc... Microscopic Res... | 31 Days - 21 Years | University of Colorado, Denver | |
| Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | NCT02611024 | Advanced Solid ... Glioblastoma Soft Tissue Sar... Endometrial Car... Epithelial Ovar... Mesothelioma Gastroenteropan... SCLC Gastric Carcino... Pancreatic Aden... Colorectal Carc... Neuroendocrine ... | Lurbinectedin Irinotecan | 18 Years - | PharmaMar | |
| A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma | NCT01723020 | Advanced Malign... Advanced Solid ... Cancer Oncology Oncology Patien... Tumors Glioblastoma Multiple Myelom... | AMG 232 | 18 Years - | Kartos Therapeutics, Inc. | |
| Expression of NIS Protein and mRNA in Thyroid Tumors | NCT00459498 | Tumors | 18 Years - 80 Years | University of Sao Paulo | ||
| A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664) | NCT00435669 | Tumors | Brivanib Brivanib | 18 Years - | Bristol-Myers Squibb | |
| NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS) | NCT00248404 | Tumors | NB1011 | 18 Years - | Kiadis Pharma | |
| Research on the Application and Mechanism of New Biological Probes in Biomedicine | NCT04977739 | Tumors Cardiovascular ... Respiratory Sys... Digestive Syste... Endocrine Syste... Metabolic Disea... Immune System D... Urinary System ... Nervous System ... Blood Diseases Infectious Dise... | No intervention | 18 Years - 70 Years | Nanfang Hospital, Southern Medical University | |
| A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors | NCT00858377 | Advanced Malign... Advanced Solid ... Cancer Solid Tumors Tumors | Arm 1- Dose Esc... Arm 1- Dose Exp... | 18 Years - | Amgen | |
| A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before | NCT00870870 | Non-Small Cell ... | Gemcitabine Cisplatin IMC-A12 (cixutu... Cetuximab IMC-A12 (cixutu... Cetuximab Carboplatin | 18 Years - | Eli Lilly and Company | |
| Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates | NCT00130936 | Gastric Cancer Esophageal Canc... Tumors | Epirubicin Carboplatin Capecitabine | 18 Years - 70 Years | AHS Cancer Control Alberta | |
| Study of Satraplatin (JM-216) in Combination With Docetaxel | NCT00125411 | Tumors | satraplatin and... | 18 Years - | Agennix | |
| A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029) | NCT00127127 | Tumors | vorinostat | 20 Years - 75 Years | Merck Sharp & Dohme LLC | |
| Data Collection in Patients Undergoing CT-Guided Needle Interventions for NeedleWays System Development | NCT02329665 | Tumors | NeedleWays™ Sys... | 18 Years - | NeedleWays | |
| Study Evaluating HKI-272 in Tumors | NCT00146172 | Breast Neoplasm... | neratinib | 18 Years - | Puma Biotechnology, Inc. | |
| GOAT; Phase I Open Label Study of CGTG-102, a GM-CSF Encoding Oncolytic Adenovirus, for Advanced Cancers | NCT01437280 | Tumors Solid Tumors | CGTG-102 | 18 Years - | Baylor College of Medicine | |
| LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma | NCT00412997 | Tumors Cutaneous T-Cel... | LBH589 | 20 Years - | Novartis | |
| Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors | NCT01155713 | Neoplasm Cancer Tumors | TKI258 | 18 Years - | Novartis | |
| Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors | NCT03182257 | Solid Tumor | ONO-7579 | 18 Years - | Ono Pharmaceutical Co. Ltd | |
| A Study of ASP1951 in Subjects With Advanced Solid Tumors | NCT03799003 | Advanced Solid ... | ASP1951 pembrolizumab | 18 Years - | Astellas Pharma Inc |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
